Search
- Page Path
- HOME > Search
Brief Report
- The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
- Hanul Park, Young Joon Park, Hye Young Lee, Mi Yu, Yeong-Jun Song, Sang Eun Lee, Ji-Joo Lee, Eun-Sol Lee, Yeonjung Kim
- Osong Public Health Res Perspect. 2022;13(6):443-447. Published online December 23, 2022
- DOI: https://doi.org/10.24171/j.phrp.2022.0262
- 1,509 View
- 159 Download
- 2 Citations
-
Graphical Abstract
Abstract
PDF 
- Objectives
On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir +ritonavir) asa treatment method that could reduce the risk of hospitalization or death for patients withconfirmed coronavirus disease 2019 (COVID-19).Methods: From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effectsof treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term carefacilities during the outbreak of the Omicron variant of severe acute respiratory syndromecoronavirus 2 in South Korea.Results: The rate of severe illness or death in the group given Paxlovid was 51% lower thanthat of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI],0.24−0.98). Compared to unvaccinated patients, patients who had completed 3 doses of thevaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13−0.64) and a65% reduced death rate (aRR, 0.35; 95% CI, 0.15−0.79).Conclusion: Patients given Paxlovid showed a lower rate of severe illness or death and alower fatality rate than those who did not receive Paxlovid. Patients who received 3 dosesof the vaccine had a lower rate of severe illness or death and a lower fatality rate than theunvaccinated group. -
Citations
Citations to this article as recorded by
-
COVID
‐19 infection in patients with haematological malignancies: A single‐centre survey in the latest Omicron wave in China
Xiaolu Zhu, Qian Jiang, Jin Lu, Yuqian Sun, Xiaosu Zhao, Shenmiao Yang, Feifei Tang, Wenjing Yu, Ting Zhao, Xiaohong Liu, Jinsong Jia, Wenbing Duan, Lijuan Hu, Jing Wang, Yang Liu, Nan Peng, Xuelin Dou, Rui Ma, Qiang Fu, Huifang Wang, Kaiyan Liu, Xiaojun
British Journal of Haematology.2023;[Epub] CrossRef - The association mental health of adolescents with economic impact during the COVID-19 pandemic: a 2020 Korean nationally representative survey
Hanul Park, Kang-Sook Lee
BMC Public Health.2023;[Epub] CrossRef
-
COVID
‐19 infection in patients with haematological malignancies: A single‐centre survey in the latest Omicron wave in China
Original Article
- Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea
- Mi Yu, Bryan Inho Kim, Jungyeon Kim, Jin Gwack
- Osong Public Health Res Perspect. 2022;13(5):370-376. Published online October 18, 2022
- DOI: https://doi.org/10.24171/j.phrp.2022.0138
- 900 View
- 56 Download
-
Abstract
PDF
- Objectives
This study analyzed the clinical outcomes of remdesivir treatment in coronavirus disease 2019 (COVID-19) patients in South Korea.
Methods
This retrospective cohort study involved the secondary analysis of epidemiological data. Among patients diagnosed with COVID-19 from July 2, 2020 to March 23, 2021 (12 AM), 4,868 who received oxygen therapy and were released from isolation after receiving remdesivir treatment were assigned to the treatment group, and 6,068 patients who received oxygen therapy but not remdesivir were assigned to the untreated group. The study subjects included children under the age of 19. The general characteristics and severity were compared between the groups. Differences in the time to death and mortality were also compared.
Results
In the untreated group, the hazard ratio [HR] for mortality was 1.59 among patients aged ≥70 years and 2.32 in patients with severe disease in comparison to the treatment group. In a comparison of survival time among patients with severe disease aged ≥70 years, the HR for mortality before 50 days was 2.09 in the untreated group compared to the treatment group.
Conclusion
Patients with remdesivir treatment showed better clinical outcomes in this study, but these results should be interpreted with caution since this study was not a fully controlled clinical trial.
First
Prev
